✦ LIBER ✦

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab

✍ Scribed by María M. Katsicas; Ricardo A. G. Russo

Publisher: Springer
Year: 2009
Tongue: English
Weight: 111 KB
Volume: 28
Category: Article
ISSN: 0770-3198
DOI: 10.1007/s10067-009-1162-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of etanercept or infliximab trea

Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis

✍ Bruno Seriolo; Sabrina Paolino; Carmela Ferrone; Maurizio Cutolo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 61 KB

Use of tumor necrosis factor-α (TNF-α) a

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

✍ Sophia Li; Primal P. Kaur; Virginia Chan; Steven Berney 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 102 KB

Efficacy and safety of repeat courses of

Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis

✍ Ekaterina I. Alexeeva; Saniya I. Valieva; Tatyana M. Bzarova; Elena L. Semikina; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 538 KB

Comparison of effectiveness and safety o

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

✍ Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 108 KB

Safety and efficacy of up to eight years

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

✍ Daniel J. Lovell; Andreas Reiff; Norman T. Ilowite; Carol A. Wallace; Yun Chon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views